Caricamento...

Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy

Trametinib, a selective inhibitor of mitogen‐activated protein kinase kinase 1 (MEK1) and MEK2, significantly improves progression‐free survival compared with chemotherapy in patients with BRAF V600E/K mutation–positive advanced or metastatic melanoma (MM). However, the pivotal clinical trial permit...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Med
Autori principali: Latimer, Nicholas R., Bell, Helen, Abrams, Keith R., Amonkar, Mayur M., Casey, Michelle
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2016
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4864810/
https://ncbi.nlm.nih.gov/pubmed/27172483
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.643
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !